DBV Technologies | DBVT - Ordinary Share Capital


DBV Technologies reported $235.6M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amarin USD 20.81M 13K Dec/2025
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
Galectin Therapeutics USD 61K 0 Dec/2023
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Insmed USD 216.52M 2.27M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Neurocrine Biosciences USD 100.6M 500K Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026